REGN vs RELY · P/E 14, rev $14.34B vs rev $1.26B
Regeneron Pharmaceuticals Inc (REGN) versus Remitly Global Inc (RELY) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Remitly Global Inc (RELY) is a software - infrastructure company listed on US.
Latest reported REGN revenue for 2025-12-31 was $14.34B. Net income was $4.50B. Revenue was up 1.0% from 2024-12-31 to 2025-12-31. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported RELY revenue for 2024-12-31 was $1.26B. Net income was -$37.0M. Revenue was up 33.9% from 2023-12-31 to 2024-12-31. RELY currently screens at market cap $3.77B.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. RELY currently screens at market cap $3.77B.
Not investment advice. Open the REGN and RELY stock pages for the full models.
Not investment advice.